/

Società

RI

Non verificato

RIBOMIC Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteVetrine/Shopping

3 comunicati stampa

Guarda tutti i comunicati

07/10/2025

Salute

Vetrine/Shopping

Biotecnologia

Infanzia

Medicina - Varie

Farmaceutica

Industria

RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older

Fonte

Emittente

1.00

0

05/11/2024

Industria

Salute

Vetrine/Shopping

Biotecnologia

Infanzia

Medicina - Varie

Farmaceutica

RIBOMIC Announces Positive Interim Results from Phase IIa Trial of umedaptanib pegol in Achondroplasia Demonstrating Increase in Annualized Growth Rate of up to +4.6 cm/year in Children 5 Years of Age and Older in the Low Dose Cohort

Fonte

Emittente

1.00

0

03/08/2024

Salute

Vetrine/Shopping

Biotecnologia

Infanzia

Medicina - Varie

Farmaceutica

Industria

RIBOMIC Announces Completion of Patient Enrollment in Early Phase II Study of umedaptanib pegol for Achondroplasia and Initiation of Dosing in Cohort 2 of Early Phase II Clinical Study

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0